Yeast Cells Expressing Amyloid Beta for Toxicity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools for identifying compounds or genetic factors that modulate amyloid beta-induced toxicity, which is a key factor in neurodegenerative diseases like Alzheimer's, as existing technologies are inadequate in screening assays.
Innovation Solution
A yeast cell expression system is developed using a fusion polypeptide with a signal sequence and human amyloid beta protein, allowing for the identification of compounds or genetic factors that modulate amyloid beta-induced toxicity by assessing cell growth or viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a fusion polypeptide containing a signal sequence and human amyloid beta protein is expressed in yeast cells, then the ability to identify compounds or genetic factors that modulate amyloid beta-induced toxicity is improved, but the growth and viability of the yeast cells deteriorate
Solution Approach 1:
The patent converts the harmful toxicity of amyloid beta expression into a beneficial screening tool. By intentionally expressing toxic amyloid beta in yeast cells, the system creates a selective pressure that allows identification of compounds or genetic factors that can suppress the toxicity, thus transforming the harmful effect into a useful assay for drug discovery and genetic screening
Solution Approach 2:
The yeast cell serves as an intermediary system between amyloid beta toxicity and compound testing. The yeast cells express amyloid beta and respond to test compounds, acting as a mediator that translates molecular interactions into measurable phenotypic outcomes (growth or viability changes), enabling high-throughput screening without directly testing compounds on human neural tissue
2Adaptability or versatility
If amyloid beta is expressed in yeast cells for screening purposes, then the capability to discover therapeutic compounds is improved, but the complexity of the expression system increases
Solution Approach 1:
The patent creates a simplified copy or model system - yeast cells expressing human amyloid beta - that replicates the essential toxicogenic properties of amyloid beta in human neurons. This model system copies the key pathological feature (amyloid beta toxicity) in a simpler, more manageable organism, enabling screening without requiring complex human neural tissue cultures or animal models
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system enables the identification of compounds or genetic factors that can prevent or suppress amyloid beta-induced toxicity, providing potential therapeutic options for neurodegenerative diseases such as Alzheimer's.
Implementation Method 1
A signal sequence causes a polypeptide to be targeted to the endoplasmic reticulum within a cell. In some embodiments, the signal sequence is located at the amino terminus of the polypeptide encoded by the expression construct. In some embodiments, the signal sequence is one that directs co-translational transport of the encoded polypeptide.
Data Source
AI summary
Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human amyloid beta protein. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress amyloid beta-induced toxicity and genetic suppressors or enhancers of amyloid beta-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease.